At present, PhIRDA has established 13 Specialty Committees. Leveraging the resources of experts and members, PhIRDA has conducted a great deal of effective work in areas including the research and development of drugs and medical devices, clinical research, industry supervision, policy research, investment and financing, digitization of drugs and medical devices and compliance. The committees aim to deliver more diversified and valuable services for PhIRDA members and the entire pharmaceutical industry, obtaining widespread attention and acclaim from various sectors of society.

Drug R&D Specialty Committee aims to promote the innovation and research ability of PhIRDA member through strengthening the communication of drug R&D; participate in the revision of domestic and foreign ICH guidelines and related technical documents, and put forward suggestions for further standardizing drug R&D and harmonization.

Clinical Research on Cardiovascular Drugs, Cranial Nerve Drugs, Oncology Drugs, Diabetes and Metabolic Diseases Drugs Specialty Committees, and Clinical Trial Research Specialty Committee, aim to promote the relevant abilities by enhancing the research on innovative drug R&D and clinical trial.

Medicinal Policy Specialty Committee aims to research on domestic and foreign medical and pharmaceutical policies theoretically and practical, aims to provide guidance and suggestions to government ministries and departments for their decision making.

Pharmaceutical Innovation Investment Specialty Committee aims to stimulate the close cooperation between investment institutions and innovators, enhance the efficiency and effectiveness of innovation, and build an open environment for medical and pharmaceutical investment.

Innovation R&D Services Specialty Committee aims to providing service for innovative drug R&D with international standardization, to create an international competitive new drug R&D service group, to enhance the transfer of innovation achievements.

International Regulatory Science Specialty Committee aims to assist government departments to further improve China's drug administration system, level up the international competitiveness of Chinese pharmaceutical enterprises, and promote the overall transformation, upgrading and innovative development of pharmaceutical industry in China.

Ethics and Business Compliance Specialty Committee aims to promote compliance system of China’s pharmaceutical enterprises, raise the awareness of risk management and compliance, and promote the healthy ecosystem of Chinese pharmaceutical industry.

Digital Medicine and Innovative Therapy Specialty Committee aims to conduct policy research, foster integration of financing with the industry, and establish cross-border platforms for exchange and cooperation to promote the flourishing innovative development of pharmaceutical digitalization in China.

Innovative Medical Devices Specialty Committee aims to establish a platform for effective exchanges among the government, industry, academia, research, application, and clinical, to promote regulatory supervision, technological R&D, clinical applications, and transformation of outcomes in the innovative medical devices industry.

All specialty committees allow related experts to join personally and provide guidance and consultation on policies, technological innovation, clinical research, investment and financing, and R&D service to provide practical services to PhIRDA members.